Ipilimumab (3 mg/kg)

DRUG3 trials

Sponsors

Biogen, University College, London, University of Texas Southwestern Medical Center

Conditions

GlioblastomaGlioblastoma - CategoryGliosarcoma, AdultHepatocellular Carcinoma (HCC)MelanomaMetastatic (Stage IV) MelanomaUnresectable (Stage III) Melanoma

Phase 1

RTA 408 Capsules in Patients With Melanoma - REVEAL

CompletedNCT02259231

BiogenMelanoma, Metastatic (Stage IV) Melanoma, Unresectable (Stage III) Melanoma

Start: 2014-10-31End: 2018-07-23Updated: 2025-06-04

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

RecruitingNCT07134842

University College, LondonGlioblastoma, Glioblastoma - Category, Gliosarcoma, Adult

Start: 2025-07-10End: 2028-01-01Target: 16Updated: 2026-04-09

Phase 2

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

RecruitingNCT07689175

University of Texas Southwestern Medical CenterHepatocellular Carcinoma (HCC)

Start: 2026-08-21End: 2032-10-31Target: 60Updated: 2026-08-25

Related Papers

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

2017-08-2938 citations